and shares of eli lilly getting a boost as an analyst gives it a big thumbs up.his pharma stock the right medicine for your portfolio? you're watching "fast money," live from the nasdaq market site in times square. we're back right after this. so, you're 45. that's the perfect age to see some old friends, explore new worlds, and to start screening for colon cancer. yep. with colon cancer rising in adults under 50, the american cancer society recommends starting to screen earlier, at age 45. i'm cologuard, a noninvasive way to screen at home, on your schedule. and i find 92% of colon cancers. i'm for people 45+ at average risk for colon cancer, not high risk. false positive and negative results may occur. ask your provider if cologuard is right for you. power e*trade's easy-to-use tools like dynamic charting and risk-reward analysis help make trading feel effortless and its customizable scans with social sentiment help you find and unlock opportunities in the market with powerful, easy-to-use tools power e*trade makes complex trading easier react to fast-moving ma

we have been steadfast with eli lilly.th them. >> eli lilly just had an upgrade recently? the alzheimer drug was not even priced into that upgrade. yet here we are. we have this call option. >> i was surprised how much it was off. at one point, it was 10%. i like eli lilly. for me it is driven by -- and thinking weight loss drugs. >> right. >> courtney? >> what is interesting about this too is right now we are getting really good data coming out. the second piece of it is, it needs to go through medicare. we've seen it before where there have been promising drugs and it doesn't get through the medicare reimbursement program. medicare covers like 64 million people and most people with alzheimer's are on medicare. that's why these drugs need to get through the medicare reimbursement program. that is the second piece of the story. >>> coming up, target takes off. the retail giant jumping after some announcements of early holiday deals. is this one a bull's-eye bet? how they are playing this jump, when fast money returns. >> g

one thing we just talked about going into the break was eli lilly. here's the sad part.n covid hit, we locked down -- half the country locked down we literally told people, do not go outside that's exactly the wrong thing to do. and millions of -- tens of millions of americans gained a significant amount of weight eli lilly has some promising new drugs to tackle what is no doubt a crisis, an obesity crisis. one reason you like that stock >> it's a big reason we like that stock we're talking this morning about their alzheimer's drug, but i think the obesity drug is even bigger this is a drug that's coming on the back of a couple of drugs that have come out, but their drug monjora is basically promising to top even the best results that have come out in terms of clinical trials it's been approved for diabetes and is on the docket to be approved for obesity and the drug is not only effective, but it also reverses, you know, things like diabetes it reduces heart risk and all sorts of other things that are eventually expensive down the road this is a big market for them. this

eastern time. >>> shares of eli lilly popping today after ubs upgraded its rating from buy to hold andrget to $363 from $335. the rating change comes after a key weight loss drug showed promise in a recent study and could become the biggest drug ever joining us now, ubs analyst colin bristo colin, thanks for joining us obviously there's been excitement certainly around this drug it's seemingly been in the market to some degree. what is your call based on in terms of where that can go revenue-wise and why do you think the market hasn't already figured it out >> i think a couple things to point out here right? so the drug launched for diabetes in may. to date the most successful launch in diabetes ever. we had, accidentally data after that, where this out-sized opportunity comes from and the drug showed best in class ever from a therapeutic in diabetes, and it's a headline data point the drug led to a 21% meme reduction in body weight, which, to put this in context with bariatric surgery in the ballpark of 25%. so really this is a new paradigm of treatment, or could be, in obesity, and r

eli lilly -- the new all-time is drug. lauren: up 7% because the drug is reigniting hope that by targeting a particular protein, that is effective in slowing the progression of alzheimer's and brain disease and eli lilly, they hope this is a breakthrough and they will lift all those, all companies that have traded. stuart: it was up 40%, extraordinary move. lauren: they are up 3.4%, laying off 9% of their workforce, part of a major restructuring plan. a one flight attendants at united picketed over a dozen airports yesterday. the issue? lauren: 14 airports, blaming management for operational disruptions that happen over and over again and they mess up not only flight attendant schedules but then they deal with passengers who are annoyed and it is not things that you can't budget for but they cited a recent example that united failed to inspect as they were supposed to the boeing jets and had to cancel flights. just forgot. didn't do it and they say stuff like that for management is not acceptable. stuart: of lesser importa

they bet a lot on alzheimer's and also eli lilly.s important so even if the trial doesn't go well they have enough things going on like obesity drug they have that could boost the stock in the future. jack: three pics from the story that caught your eye? jack: lily is favorably mentioned and three more in an active extreme generosity. boston scientific make medical equipment, pacemakers, spinal cords, scopes, patients pool of electric procedures during the pandemic and going back including for routine tests, turned 50 a couple weeks ago. i understand become more fill you with the scopes from the portfolio soon. growth is strong, united health one of our panelists because that one of the best positioned healthcare services companies in the world, that and technology going down and it cells and finally this hugely profitable drug called humira which will face competition next year. it is 12 times next year's earnings but there are other drugs and growth will pick up after that. jack: thank you for that, we couldn't leave the segment wi

and by the next day, every other company, like cummins, and eli lilly in indiana, and hundreds of othernies, even companies all over the world said, "we agree with marc. we're also going to disinvest." and mike pence called me and said, "well, what are we going to do?" and i'm like, "i think we're going to have to issue rolling economic sanctions against the state of indiana." [laughter] and he's like, "well, what does that mean?" i'm like, "i don't know, but i think it's gonna be bad." and he's like, "well, what should we do?" i'm like, "why don't we just resolve this? you know, we know each other. this is not that hard." and, in fact, i sent two of my employees to his office. and within a couple days, it was worked out. he changed the law, and it was all behind us. and by the way, i think that's how it should work anyway. you know, it was very easy. [applause] david: now, you did a similar thing not long ago when, in san francisco, there was a tax that was proposed to help pay for homelessness, which is a big problem in san francisco. most ceos in the tech world said, this was crazy.

. >>> well, mike, netflix is up 9.5%, the second-best performing in the triple qs, and eli lilly, alsonovation -- >> so a combination of the tough that's been beaten down the most some of the largest blue-chippy stocks like an amazon perhaps it's much more about apple is considered to be the safe haven, those things kind of back off and crack a bit. that to me is the main dynamic going on right now about two minutes to go in the trading day. still holding on to a 600-point rally. what do you see? >> very strong 9 to 1, almost 10 to 1 slants advancing to declining volume. that's obviously very strong, something like 90% that's what you look for take a look at year to date the ten-year treasury yield. you'll see three pretty well-defined spikes, up to a high and then down the first one was in may, second in june, it rants about 3.5. this latest one, ran about 4%, all dramatic spikes down it did usher in a more stable equity market, once it got the bids that they were going to stick. we'll see if that repeats. the good news is went up to the mid 30s, where it has peaked out over the last

national bank who will give us a bird's-eye view from main street but first a look at shares of eli lilly. already said eli manning outperforming the market after their weight loss drug being called potentially the biggest ever with an estimated sales potential of 25 billion. >> i see what you did there. bigger bigger, weightier. personalized financial advice from ameriprise can do more than help you reach your goals. i can make this work. it can help you reach them with confidence. no wonder more than 9 out of 10 of our clients are likely to recommend us. ameriprise financial. advice worth talking about. >>> welcome back to "power lunch. inflation is making the upcoming holiday season trickier for retailers. this year walmart says it will hire 40,000 workers, a big decrease in the 150,000 workers it hired last year target instead is hiring the same number of workers as last year 100,000 but it's offering holiday deals and promotions a little bit earlier here to discuss what this says about the consumer, retailers and the economy is the ceo good to see you. >> good to see you. >> is it in

another winner for you, eli lilly, the fti has approved one of its cancer drugs at ubs upgrades them to a buy, up 3. 5%. %. it has a new weight loss drug that is considered very effective and ubs says it could be the biggest drug ever for the company. ashley: wow. i want to get into this. retailers getting a head start preparing for the holiday season. what are they doing? lauren: my kids already started their lists. you know what? i am fine with it because things are expected. what retailers are doing is making it as convenient and as cheap as possible to shop this year. walmart is now offering curbside returns, stay in your car and return your item. if you are a walmart plus member you can call a delivery person to come to your doorstep, hand them the item, don't need a box, label, nothing. amazon is rumored to have another prime day perhaps in october 2nd juice sales. inventories are surging, lululemon inventories up 85% from last year, look at these numbers, footlocker, kohl's, gap, no merchant wants that stock in the new year so they will cut the prices and they also know that w

that brings me to eli lilly. talking about this may be the biggest drug of all time, a drug that's a weight loss drug with no side effects and that is propelling a lot of the analysts to say, this is the one toown. my trust owns it i believe this is the stock you can buy. it's down, you have to find something in tech to buy, as tough as it is. >> you're right about lilly, ubs buys, 363. pretty interesting tonight you have slack and splunk >> slack is owns by salesforce but it's such an important driver of their business, i have to speak to stewart. and gary steele is turning around splunk. people are saying, i don't care what the fed does, we have to find out it is a free-falling market. when it's nine to one, find something to buy that's what i'm going to do as soon as i leave the desk. >> jim, we have a lot of work to do today before the week is out. vix back above 28. the sentiment, as you said, lousy, as we expected, going into the back half of september. we'll see you tonight on "mad money," 6:00 p.m. easter

i got a question about eli lilly and company and just for the record, i worked there in new product clients and sales and so i seen you had ricks on, david ricks -- >> yes, he's been on a couple times. look, let me just tell ya, this is a big holding for my charitable trust we almost decided to buy more now. we do fear the drug stocks can go lower because it's a high price earnings but i think the future for lily isi is unbeliev. i know you work there. hold on to it if you got stock and buy more when it breaks into the 280s it may do that because this market is bad. thank you for the kind words because this is one tough job i got now. let's go to tyler in california, tyler? >> caller: big boo-yah from california, jim, how are you doing? >> i'm looking for you i don't see ya i'm sure you're here what's up? >> caller: i'm looking at the charts for the potential bear market plays i want to know if you think this is a bottom on ticker er kr, kroger. >> doing a fantastic job i think the bottom is in hand but the chart is so bad people keep selling and selling and selling. let's say 43 how about

for the total and it's up 20% and investors have taken notice, and the other position we own is eli lillys of late, and there's been a lot of positive developments in the trials of biogen as you've seen, the alzheimer's drug, and it's obviously something that afflicts a ton of people globally and all these stocks benefit from the investment and those spaces >> joe, when we did our stock summit many months ago you picked united health, and health care is your space you own abbvie today, cgen. >> i've been active there and sold recently, used the capital to go into cgen by ownership of merck on any pull back i'd like to own to. bristol myers i don't own it that's been working well got my eye on intuitive surgical right here and might take a position on that name. also keeping an eye on abbvie and i think a name that brin in the past and i apologize if she's still in it that's pulled back recently and looks attractive here. >> you mentioned abbvie. everyone seems to like that. let's talk about energy. coming up still leading on the year we'll find out how we're playing it into the end of thi

we did the same thing mid-august along with eli lilly, h & r block, vertex, all of which i talked about on the show since then every one of them has outperformed apple apple is up in line with the market so i think when you have a stock that trades at 27 times next year's earnings and it's trading at a 15% premium to its long-term average, 50% to its peers, i'm hoping i'm wrong on this because me and a lot of other people hide in apple because of the earnings quality of the name. but since the latest highs on the bear market bounce, it's been a market performer. so you clearly have to think outside of apple if you want to generate some alpha. >>> coming up, nice gains for broadcom on the back of its earnings stephanie link owns it, icwhh is why she's calling in next. find out what she's doing with that stock when we come back (vo) hi. we're visible. a different kind of wireless company... ...running on a big impressive wireless network. how are we different? we exist only on your phone. so you get unlimited data for just $30/mo, taxes and fees included. plus we have a new plan with 5g u

ishares etfs up nearly 4% other companies working on alzheimer's treatments getting a boost including eli lillynd hitting an all-time high let's get a check on what's happening in florida and other news, the cnbc news update and seema moody. >> here's what's happening the eye of hurricane ian is just 25 miles from fort myers, florida. it remains a strong category 4 storm with sustained winds of 155 miles per hour and gusts reaching 190 miles per hour. ian is expected to slow down when it comes ashore and dump 12 to 18 inches of rain across a broad swath of the state. >>> in the baltic sea the nord stream natural gas leak may be the equivalent of 16 million tons of carbon dioxide released into the atmosphere. a danish official says that's a third of denmark's carbon dioxide emissions. >>> and lehman brothers, remember them, liquidation of its brokerage unit ended 14 years, 13 days after the company filed for bankruptcy and helped trigger the financial crisis in all more than $115 billion was paid out customers and secured creditors received all the money they were owed and unsecured creditors go

eli lilly and regeneron and bio again. we'll put that on the watch list.ith greatest earnings in revenue growth -- [audio issues] charles: don't force the issue. thank millions have made the switch from the big three to the best kept secret in wireless: xfinity mobile. that means millions are saving hundreds a year with the fastest mobile service. and now, introducing, the best price for two lines of unlimited. just $30 per line. there are millions of happy campers out there. and this is the perfect time to join them... add a line to your existing plan, or see for yourself how easy it is to save by talking to our helpful switch squad at your local xfinity store today. ♪. charles: i don't need to tell you terrible year for stocks and bonds. when you look under the hood, folks, the damage far worse than you assume. look for instance at the advance-decline line. this is the lowest level of the year certainly, and lowest level going all the way back to september, october much last year. and there is little improvement right to new highs and new lows. again i t

>> eli lilly, i think the process in the pipeline is a stock that can do well. >> karen?ize, google is so much better. alphabet on the final trade. >> so there, dan. tim? >> matt has the under on the jets, i'm going caesars. >> thanks so much for watching fast money. we will see you back here tomorrow. don't go anywhere, cnbc special blue-chip playbook starts >>> hello everyone and welcome to the cnb special, blue-chip playbook. the goal this hour is to give investors a guide to investing in the blue-chip. large companies, brand names with established trend records and solid dividend earners. we broke in data t

on the flip side, health care stocks are outperforming today eli lilly getting a double dose of goods the fda approving its cancer drug for new uses. merck is leading the down after one of its cancer drugs was approved for use in china. let's step out of the markets and get a cnbc news update with tyler mathisen >> hi, brian welcome, everybody here's your cnbc news update, up to the minute. an indiana judge has issued an order blocking that stale's abortion ban from going into effect the ban was passed in early august and abortion rights groups sued to block the law the judge said the ban, with its limited exceptions violated the state's constitution and is a, quote, significant restriction of personal autonomy >>> a mississippi official has pleaded guilty to conspiracy to commit fraud and theft in the scandal that improperly paid out millions of welfare dollars across the state john davis was a key figure in the state's welfare agency and the charges carry a minimum -- a maximum, excuse me, of 15 years in prison. remember, some of this welfare money went toward paying for a new voll

it's eli lilly reportedly on the hunt for a large expansion in south san francisco. so bizjournals reports the company looking for 300,000 square feet of additional space in the area. multiple sources with knowledge of the company's real state strategy confirmed that in a lot of details, the company already has 2 south san francisco locations that is looking to expand. well, president biden announced new rules requiring airlines and travel sites to be more transparent about fees that customers could be charged under these proposed rules. airlines and travel sites would have to disclose up front the first time in airfares just played any feature charge to sit with your child or changing a flight and for checked or carry on baggage. the administration still hasn't finalize the rules. they are currently seeking public input and as interest rates rise, some savings accounts are suddenly going up an interest. in fact, some are paying 3% interest. it is below inflation, but it's better than we were the beginning of the year, which is about a half percent. those are levels

eli lilly is having a monster quarter and a monster year these are real companies, david.nited health is doing amazingly. they keep raising the prices if united health came on, they would say, well, our price increases are sticking and people need us >> we talked about humana. >> my travel trust is in humana. i switched to humana because they were offering a program that wasn't that great they changed the offering. anybody who listened to it, the offering is much better. and then i got micron, and i'm thinking, okay, what happens -- i happen to like qualcomm very much i've been very wrong i like christian but what do i do when the number comes out and it's not good? what do i do just say, hey, that's not my job? it's fine? i can take a beating the beatings will continue until the morale gets better >> it's the conundrum that many investors are facing right now >> why do we have to buy companies that aren't doing well when we could buy really good companies that are doing well and the stocks are going higher? what's the matter with that? >> there's nothing wrong with that i

. >> what was up $28 >> stock of eli lilly. >> oh, they were up for.eanwhile, biogen is advancing by almost 38.7%. again, on what would be amazing news for those who are suffering from this horrible disease and the family members who do, which is the idea that if you were to take something -- again, 27%, but that's better than zero in terms of actually arresting the progression of the disease or slowing the progression of the disease. we'll have to wait and see we've been down this road before with biogen, to some extent. and it didn't particularly end well >> and i know no one wants to hear this, but the studies that have been successful involve taking it far earlier, so that you prevent alzheimer's rather than if you have it already. and that means one of the reasons why the government, i think, has been reluctant, carl, is that you're talking about perhaps even taking it 20 years before you have it, and you have to see your bloodlines are there people in your family who have had it? >> my god, the costs would be astronomical, potentially, for the go

>> all i got on my screen is merck, bristol-myers >> i think you should add eli lilly. to get their weight drug and i believe their alzheimer's is going to be as good as biogen the weight drug. loses weight no downside. >> send me more information. i'm interested another day of washout let's get to bob pisani. >> good morning, guys. and we basically given up all the gains that we had yesterday. david had a great point, it's really hard to put on risk in this market because the market's picking your pocket here day after day, you're getting faked out here, and it's making it really difficult so i use very simple metrics for risk on, risk off arc innovation, semiconductors, metals and mining, these are good examples of risk on, risk off, all three of them down 2.5 to 4% today. everything else within that range. banks, consumer staples doing a little bit better, but not much bett better if you look at mega cap tech, bank of america downgrade for apple here, lowest level since july apple's held up better but it was 176 in august so we're down 15% since then there's amd and

rival drugmakers including eli lilly also moving on the news.l with alzheimer's, what the root cause is, what's a cause, what's a symptom -- >> plaque. clearing out the plaque seemed to make a difference in this study. >> we don't know whether that was the result or the cause. it's very difficult epidemiology of alzheimer's one thing we do know is that there's an aging population and it could become a -- just a heartbreaking thing for families and also something that would be very, very costly. >> and at this point medicare would not pay for some of it this new study would probably make it much more likely for them to pay for some things because alzheimer's is very expensive. if you can find a drug, you could save -- you could save this population. >>> in the meantime, ford unveiling it's next generation superduty truck amid supply chain challenges phil lebeau joins us now. >> good morning. we've got on our first glimpse at the new superduty when ford unveiled it's an important vehicle for ford 35% of the f series sales are superduty trucks it g